Navigating the Atopic Dermatitis Toolbox: Challenging Scenarios and Shared Decision Making

Document Type

Journal Article

Publication Date

12-23-2023

Journal

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

DOI

10.1016/j.anai.2023.12.020

Keywords

JAK inhibitors; atopic dermatitis

Abstract

Atopic Dermatitis (AD) is a chronic inflammatory disease with a complex pathogenesis and heterogeneous clinical presentation. Recently, multiple advanced therapies were approved for the treatment of moderate-severe AD, including the biologics dupilumab, tralokinumab and lebrikizumab, and oral Janus Kinase (JAK)-inhibitors abrocitinib, upadacitinib and baricitinib. These treatments have different efficacy, safety and tolerability profiles and monitoring requirements. The availability of multiple recently approved therapies poses a clinical challenge for healthcare providers and patients on how to select the best treatment for patients. This article aims to highlight clinical considerations and patient perspectives to guide shared decision-making for biologic and oral systemic therapy, particularly JAK-inhibitors, in AD. Important aspects to consider include treatment goals, medical history, symptom severity, physician assessments, safety profile of drugs and the risk predispositions in patients.

Department

Dermatology

Link to Full Text

Share

COinS